Last updated on September 2018

A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 (NCT02833350)


Brief description of study

This is a Phase II, multicenter, open-label extension study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active RA who have completed 12 weeks of study treatment in Study GA29350 (NCT02833350). Eligible participants from Study GA29350 who elect to participate will receive treatment with GDC-0853 twice daily (BID) in an open-label fashion for 52 weeks, followed by a safety follow-up period of 8 weeks.

Clinical Study Identifier: NCT02983227

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: GA30067 ...

Instituto de Investigaciones Clinicas-Mar del Plata
Buenos Aires, Argentina
  Connect »

Reference Study ID Number: GA30067 ...

Organizacion Medica de Investigacion
Buenos Aires, Argentina
  Connect »

Reference Study ID Number: GA30067 ...

Hospital Italiano
Buenos Aires, Argentina
  Connect »

Reference Study ID Number: GA30067 ...

Instituto centenario
Buenos Aires, Argentina
  Connect »

Reference Study ID Number: GA30067 ...

Centro de Investigacion en Enfermedades Reumaticas CIER
Ciudad Autonoma Buenos Aires, Argentina
  Connect »

Reference Study ID Number: GA30067 ...

Expertia S.A- Mautalen Salud e Investigaci n
Ciudad Autonoma Buenos Aires, Argentina
  Connect »

Reference Study ID Number: GA30067 ...

CCBR - Buenos Aires - AR; AxisMed SRL
Ciudad Autonoma Buenos Aires, Argentina
  Connect »

Reference Study ID Number: GA30067 ...

Instituto de Investigaciones Neurologicas Raul Carrea FLENI
Capital Federal, Argentina
  Connect »